Your browser doesn't support javascript.
loading
Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases.
Ishikawa, Kiyohito; Hamasuna, Ryoichi; Uehara, Shinya; Yasuda, Mitsuru; Yamamoto, Shingo; Hayami, Hiroshi; Takahashi, Satoshi; Matsumoto, Tetsuro; Minamitani, Shinichi; Kadota, Jun-ichi; Iwata, Satoshi; Kaku, Mitsuo; Watanabe, Akira; Sunakawa, Keisuke; Sato, Junko; Hanaki, Hideaki; Tsukamoto, Taiji; Kiyota, Hiroshi; Egawa, Shin; Deguchi, Takashi; Matsumoto, Minori; Tanaka, Kazushi; Arakawa, Soichi; Fujisawa, Masato; Kumon, Hiromi; Kobayashi, Kanao; Matsubara, Akio; Wakeda, Hironobu; Amemoto, Yoshinosuke; Onodera, Shoichi; Goto, Hirokazu; Komeda, Hisao; Yamashita, Masuo; Takenaka, Tadasu; Fujimoto, Yoshinori; Tsugawa, Masaya; Takahashi, Yoshito; Maeda, Hiroshi; Onishi, Hiroyuki; Ishitoya, Satoshi; Nishimura, Kazuo; Mitsumori, Kenji; Ito, Toru; Togo, Yoshikazu; Nakamura, Ichiro; Ito, Noriyuki; Kanamaru, Sojun; Hirose, Takaoki; Muranaka, Takashi; Yamada, Daisuke.
Afiliación
  • Ishikawa K; Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Fujita Health University School of Medicine, Aichi
  • Hamasuna R; Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, University of Occupational and Environmental Healt
  • Uehara S; Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Okayama University Graduate School of Medicine, De
  • Yasuda M; Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Graduate School of Medicine, Gifu University, Gifu
  • Yamamoto S; Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Hyogo College of Medicine, Hyogo, Japan.
  • Hayami H; Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Blood Purification Center, Kagoshima University Hospital, Kagoshima, Japa
  • Takahashi S; Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Sapporo Medical University School of Medicine, Sap
  • Matsumoto T; Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, University of Occupational and Environmental Healt
  • Minamitani S; Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Disease (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Kadota J; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
  • Iwata S; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
  • Kaku M; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
  • Watanabe A; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
  • Sunakawa K; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
  • Sato J; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
  • Hanaki H; Research Center for Anti-infectious Drugs, Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan.
  • Tsukamoto T; Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Kiyota H; Department of Urology, The Jikei University Katsushika Medical Center, Tokyo, Japan.
  • Egawa S; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Deguchi T; Department of Urology, Graduate School of Medicine, Gifu University, Gifu, Japan.
  • Matsumoto M; Division of Urology, Kobe University Graduate School of Medicine, Hyogo, Japan.
  • Tanaka K; Division of Urology, Kobe University Graduate School of Medicine, Hyogo, Japan.
  • Arakawa S; Division of Urology, Kobe University Graduate School of Medicine, Hyogo, Japan.
  • Fujisawa M; Division of Urology, Kobe University Graduate School of Medicine, Hyogo, Japan.
  • Kumon H; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Kobayashi K; Department of Urology, Institute of Biomedical & Health Sciences Hiroshima University, Hiroshima, Japan.
  • Matsubara A; Department of Urology, Institute of Biomedical & Health Sciences Hiroshima University, Hiroshima, Japan.
  • Wakeda H; Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Amemoto Y; Department of Urology, Minami Medical Health Cooperation, Aichi, Japan.
  • Onodera S; Department of Urology, Fuji City General Hospital, Shizuoka, Japan.
  • Goto H; Department of Urology, Fuji City General Hospital, Shizuoka, Japan.
  • Komeda H; Department of Urology, Gifu Municipal Hospital, Gifu, Japan.
  • Yamashita M; Department of Urology, Shinko Hospital, Hyogo, Japan.
  • Takenaka T; Department of Urology, Japanese Red Cross Okayama Hospital, Okayama, Japan.
  • Fujimoto Y; Department of Urology, Ogaki Municipal Hospital, Gifu, Japan.
  • Tsugawa M; Department of Urology, Okayama City Hospital, Okayama, Japan.
  • Takahashi Y; Department of Urology, Gifu Prefectural General Medical Center, Gifu, Japan.
  • Maeda H; Department of Urology, Yodogawa Christian Hospital, Osaka, Japan.
  • Onishi H; Department of Urology, Shiga Medical Center for Adults, Shiga, Japan.
  • Ishitoya S; Department of Urology, Shiga Medical Center for Adults, Shiga, Japan.
  • Nishimura K; Department of Urology, Osaka Red Cross Hospital, Osaka, Japan.
  • Mitsumori K; Department of Urology, Osaka Red Cross Hospital, Osaka, Japan.
  • Ito T; Department of Urology, Nagoya Ekisaikai Hospital, Aichi, Japan.
  • Togo Y; Department of Urology, Hyogo College of Medicine, Hyogo, Japan.
  • Nakamura I; Department of Urology, Kobe City Medical Center West Hospital, Hyogo, Japan.
  • Ito N; Department of Urology, Nishi Kobe Medical Center, Hyogo, Japan.
  • Kanamaru S; Department of Urology, Nishi Kobe Medical Center, Hyogo, Japan.
  • Hirose T; Department of Urology, Japan Community Health Care Organization Hokkaido Hospital, Hokkaido, Japan.
  • Muranaka T; Department of Urology, Japan Community Health Care Organization Hokkaido Hospital, Hokkaido, Japan.
  • Yamada D; Department of Urology, Mitoyo General Hospital, Kagawa, Japan.
J Infect Chemother ; 21(9): 623-33, 2015 Sep.
Article en En | MEDLINE | ID: mdl-26166322
To investigate antimicrobial susceptibility patterns of various bacterial pathogens isolated from complicated urinary tract infection (UTI) cases, the Japanese Society of Chemotherapy, the Japanese Association of Infectious Disease, and the Japanese Society of Clinical Microbiology conducted the second nationwide surveillance from January to September 2011. With the cooperation of 42 medical institutions throughout Japan, 1036 strains belonging to 8 clinically relevant bacterial species were collected. Among methicillin-resistant Staphylococcus aureus (MRSA) strain, the vancomycin (VCM) MIC for 5.5% (3/55) of the strains was 2 µg/mL. Ampicillin, VCM, and linezolid were relatively active against 209 Enterococcus faecalis strains. The proportion of fluoroquinolone (FQ)-resistant strains was >20%. The MIC90 of FQs against the 382 Escherichia coli strains was 2-64 mg/L and the proportion resistant to FQs was approximately 30%. However, susceptibility of E. coli to sitafloxacin was still high (MIC90 = 2 mg/L). Fifty-eight (15.2%) of 382 E. coli, 6 (4.5%) of 132 Klebsiella pneumoniae, 1 (2.4%) of 41 Klebsiella oxytoca and 4 (6.8%) of 59 Proteus mirabilis strains were suspected of producing extended-spectrum beta-lactamase. Of 93 Pseudomonas aeruginosa strains, the proportions resistant to imipenem, amikacin, and ciprofloxacin were 21.5%, 4.3%, and 20.4%, respectively. Four strains (4.3%) were found to be multidrug-resistant. In complicated UTI cases, all of MRSA and E. faecalis were susceptible to all anti-MRSA agents. Sitafloxacin was active against other FQ-resistant E. coli strains. The isolation of extended-spectrum beta-lactamase-producing and multidrug-resistant strains increased.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones Urinarias / Vigilancia de la Población / Enterococcus faecalis / Staphylococcus aureus Resistente a Meticilina / Bacterias Gramnegativas / Antibacterianos Tipo de estudio: Screening_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: J Infect Chemother Asunto de la revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2015 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones Urinarias / Vigilancia de la Población / Enterococcus faecalis / Staphylococcus aureus Resistente a Meticilina / Bacterias Gramnegativas / Antibacterianos Tipo de estudio: Screening_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: J Infect Chemother Asunto de la revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2015 Tipo del documento: Article Pais de publicación: Países Bajos